Disease/Infection News

RSS

Experiments to probe bacteria virulence in low gravity of space station

The University of Colorado Boulder will fly state-of-the-art hardware on the commercial SpaceX Dragon spacecraft launching to the International Space Station Dec. 19 to support experiments designed to better understand why the virulence of some pathogens increases in the low gravity of space.

14 Dec 2014

Laurie T. Krug named Stony Brook University Discovery Prize Fellow

Laurie T. Krug, an Assistant Professor in the Department of Molecular Genetics and Microbiology at Stony Brook University, is the first early career scientist to be named Stony Brook University Discovery Prize Fellow, a new philanthropically-sponsored award established to fund high-risk, high-reward basic research projects.

14 Dec 2014

Zylast selected as a winner of USAID Fighting Ebola Grand Challenge

Zylast products have been selected as one of only three initial winners of the USAID Fighting Ebola Grand Challenge. The announcement, made from the White House, introduces Zylast as a solution to "help healthcare workers on the front lines provide better care and stop the spread of Ebola."

14 Dec 2014

Improved healthcare protective suit to combat Ebola wins U.S. award

An advanced protective suit for healthcare workers who treat Ebola patients, devised by a Johns Hopkins team, has been selected as a winning design in a global competition aimed at quickly getting new tools into the field to combat this deadly disease.

14 Dec 2014

FDA approves Fluzone Intradermal Quadrivalent vaccine to prevent four strains of influenza virus

Sanofi Pasteur, the vaccines division of Sanofi, today announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for Fluzone Intradermal Quadrivalent vaccine.

13 Dec 2014

Janssen, USAID sign MOU to fight against health threat of antibiotic-resistant bacteria

Johnson & Johnson today announced that its affiliate Janssen Therapeutics, Division of Janssen Products, LP, has signed a Memorandum of Understanding (MOU) representing the intention of the Company along with the United States Agency for International Development to step up the fight against the health threat of antibiotic-resistant bacteria.

12 Dec 2014

Danish researchers working on new type of vaccine that targets disease causing bacterium

When we acquire diarrhea on a vacation, it is often caused by a bacterial infection. Now a Danish research team is working on a new type of vaccine design targeting the disease causing bacterium - if it works it may very well revolutionize not only the prevention of this disease, but also offer protection against other pathogens with a heavy disease burden such as Mycobacterium tuberculosis and antibiotic-resistant Staphylococcus aureus (MRSA).

12 Dec 2014

Study finds that K13 gene mutations cause malaria drug resistance in Southeast Asia

Growing resistance to malaria drugs in Southeast Asia is caused by a single mutated gene inside the disease-causing Plasmodium falciparum parasite, according to a study led by David Fidock, PhD, professor of microbiology & immunology and of medical sciences (in medicine) at Columbia University Medical Center.

12 Dec 2014

Study examines benefits of IS technique in assessing effect of pollution on urban asthmatic children

For the firefighters and rescue workers conducting the rescue and cleanup operations at Ground Zero from September 2001 to May 2002, exposure to hazardous airborne particles led to a disturbing "WTC cough" -- obstructed airways and inflammatory bronchial hyperactivity -- and acute inflammation of the lungs. At the time, bronchoscopy, the insertion of a fiber optic bronchoscope into the lung, was the only way to obtain lung samples. But this method is highly invasive and impractical for screening large populations.

11 Dec 2014

KU, WHO researchers partner to develop case studies to better understand new cases of Ebola

In the midst of the chaos that is the Ebola epidemic in West Africa, a small group of University of Kansas researchers is quietly partnering with their colleagues in the World Health Organization (WHO) African Regional Office. Together, they are developing case studies to help understand what has worked in those areas of Liberia where the spread of Ebola Virus Disease has waned.

11 Dec 2014

Pitt researcher receives NSF grant to explore how long Ebola virus survives in environment

The Ebola virus travels from person to person through direct contact with infected body fluids. But how long can the virus survive on glass surfaces or countertops? How long can it live in wastewater when liquid wastes from a patient end up in the sewage system? In an article published Dec. 9 in the journal Environmental Science & Technology Letters, Kyle Bibby of the University of Pittsburgh reviews the latest research to find answers to these questions.

11 Dec 2014

Scientists report new family of selective molecules to combat causal agent of malaria

Malaria is one of the most serious health problems worldwide, registering 200 million clinical cases and more than 600,000 attributable deaths per year, according to information from the World Health Organization in 2013. Given the emerging resistance to the standard treatment most widely used throughout the world, which is based on artemisinin and its analogs, there is a need for new antimalarial compounds.

11 Dec 2014

UT Southwestern microbiologists identify key gut bacteria that promotes foodborne infections

UT Southwestern Medical Center microbiologists have identified key bacteria in the gut whose resources are hijacked to spread harmful foodborne E. coli infections and other intestinal illnesses.

11 Dec 2014

Research finding could lead to development of effective vaccines against microbial infections

The diverse functions of a special cell-recognition lipoprotein, LOX-1, weren't always fully understood. However, Baylor Research Institute investigators gained better insight into LOX-1's role in immune responses through a study recently published in Immunity. Investigators found that the lipoprotein promotes humoral responses, which could allow researchers to design effective vaccines against microbial infections, including influenza viruses and HIV.

11 Dec 2014

New study investigates Ebola protein

A new study by Robert Stahelin, an adjunct associate professor of chemistry and biochemistry at the University of Notre Dame and an associate professor at the Indiana University School of Medicine-South Bend, as well as a member of Notre Dame's Eck Institute for Global Health, investigates how the most abundant protein that composes the Ebola virus, VP 40, mediates replication of a new viral particle.

11 Dec 2014

Potential new active substances for treating dengue virus

Researchers from Johannes Gutenberg University Mainz and the Julius Maximilian University of Würzburg are proposing potential new active substances for treating the dengue virus. Just like Ebola, dengue fever is also caused by a virus for which there is currently no cure and no vaccine and can be fatal.

11 Dec 2014

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

11 Dec 2014

Simple tips to keep families safe from flu

The flu, or seasonal influenza virus, is extremely unpredictable. Its severity can vary widely from one season to the next depending on many things, including the strains of flu spreading, availability of vaccines, how many people get vaccinated and how well the flu vaccine is matched to the flu viruses circulating each season.

10 Dec 2014

Treatment guidelines lacking for Ebola patients, say infectious diseases experts

As the Ebola Virus Diseases (EVD) epidemic continues to rage in West Africa, infectious diseases experts call attention to the striking lack of treatment guidelines. With over 16,000 total cases and more than 500 new infections reported per week, and probable underreporting of both cases and fatalities, the medical community still does not have specific approved treatment in place for Ebola, according to an editorial published in the International Journal of Infectious Diseases.

10 Dec 2014

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.

10 Dec 2014

Disease/Infection News

Experiments to probe bacteria virulence in low gravity of space station

Laurie T. Krug named Stony Brook University Discovery Prize Fellow

Zylast selected as a winner of USAID Fighting Ebola Grand Challenge

Improved healthcare protective suit to combat Ebola wins U.S. award

FDA approves Fluzone Intradermal Quadrivalent vaccine to prevent four strains of influenza virus

Janssen, USAID sign MOU to fight against health threat of antibiotic-resistant bacteria

Danish researchers working on new type of vaccine that targets disease causing bacterium

Study finds that K13 gene mutations cause malaria drug resistance in Southeast Asia

Study examines benefits of IS technique in assessing effect of pollution on urban asthmatic children

KU, WHO researchers partner to develop case studies to better understand new cases of Ebola

Pitt researcher receives NSF grant to explore how long Ebola virus survives in environment

Scientists report new family of selective molecules to combat causal agent of malaria

UT Southwestern microbiologists identify key gut bacteria that promotes foodborne infections

Research finding could lead to development of effective vaccines against microbial infections

New study investigates Ebola protein

Potential new active substances for treating dengue virus

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

Simple tips to keep families safe from flu

Treatment guidelines lacking for Ebola patients, say infectious diseases experts

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News